DAHANCA 9 – a randomized multicenter study to compare accelerated normo-fractionated radiotherapy with accelerated hyperfractionated radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC)
Sign Up to like & getrecommendations! Published in 2019 at "Acta Oncologica"
DOI: 10.1080/0284186x.2019.1629012
Abstract: Following the DAHANCA 5 trial [1], which demonstrated the benefit of the hypoxic radiosensitizer Nimorazole, and the DAHANCA 6&7 trial, which demonstrated that accelerated fractionation added signi... read more here.
Keywords: randomized multicenter; compare accelerated; study compare; dahanca randomized ... See more keywords
A randomized, multicenter study on a flexible hyaluronic acid filler in treatment of moderate‐to‐severe nasolabial folds in a Chinese population
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Cosmetic Dermatology"
DOI: 10.1111/jocd.14914
Abstract: Restylane Defyne (HARD, with lidocaine) has been shown to be effective and safe for facial augmentation including nasolabial folds (NLFs) in Caucasians. Incorporating lidocaine in injectable fillers has become a common practice that improves the… read more here.
Keywords: flexible hyaluronic; randomized multicenter; study flexible; nasolabial folds ... See more keywords
Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-labeled phase 3 trial
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Communications"
DOI: 10.1186/s40880-019-0359-7
Abstract: BackgroundThe benefit of systemic treatments in esophageal squamous cell carcinoma (ESCC) which has progressed after chemotherapy is still uncertain and optimal regimens based on randomized trials have not yet been established. We aimed to compare… read more here.
Keywords: recurrent metastatic; irinotecan plus; prospective randomized; trial ... See more keywords
Updated results of REGOMA: A randomized, multicenter, controlled open-label phase II clinical trial evaluating regorafenib in relapsed glioblastoma (GBM) patients (PTS).
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.2047
Abstract: 2047Background: There is no established treatment regimen for recurrent GBM. GBMs have activation of multiple signaling pathways in the tumor microenvironment, including the receptor tyrosine kinases, VEGFR, FGFR, and PDGFR. REG, an oral multikinase inhibitor,… read more here.
Keywords: trial; results regoma; gbm; regoma randomized ... See more keywords
A randomized, multicenter phase 3 study of durvalumab (D) and tremelimumab (T) as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC): HIMALAYA study.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.tps4144
Abstract: TPS4144Background: Thus far, sorafenib remains the standard of care for first line systemic therapy in patients with advanced HCC but patient prognosis and quality of life (QOL) continues to be poo... read more here.
Keywords: first line; study; multicenter phase; randomized multicenter ... See more keywords